BACKGROUND AND OBJECTIVE: The effects of ambulatory oxygen for idiopathic pulmonary fibrosis (IPF) patients without resting hypoxemia have not been elucidated. The purpose of this study was to assess the effect of ambulatory oxygen on dyspnea in IPF patients without resting hypoxemia but with desaturation on exertion. METHODS: This was a double-blind, placebo-controlled, randomized crossover trial of ambulatory oxygen versus ambulatory air. Patients with IPF who had a partial pressure of arterial oxygen (PaO2) between 60 mm Hg and 80 mm Hg at rest, and desaturation of 88% or less in a room-air 6-min walk test were eligible. Patients underwent a standardized 6-min walk test and a 6-min free walk test under each ambulatory gas. Oxygen and air were provided at 4 L/min intranasally. Dyspnea was evaluated immediately, 1, and 2 min after the tests. RESULTS:Twenty patients (16 men), with a mean age of 73.5 (SD 4.1) years, % predicted forced vital capacity (FVC) of 71.0 (13.3) %, % predicted diffusion capacity for carbon monoxide (DLco) of 57.0 (13.3) %, and PaO2 of 72.5 (5.4) mm Hg were recruited. No significant differences in dyspnea were observed between ambulatory oxygen and air at each time point. However, some patients showed improvement in dyspnea with oxygen on an individual basis. CONCLUSIONS: Since oxygen provides no additional benefit over air in terms of exertional dyspnea for IPF patients without resting hypoxemia, routine prescription of ambulatory oxygen is not recommended. However, assessment on an individual basis is necessary. Trial registration. UMIN Clinical Trial Registry; No.:UMIN000005098; URL:http://www.umin.ac.jp/ctr/.
RCT Entities:
BACKGROUND AND OBJECTIVE: The effects of ambulatory oxygen for idiopathic pulmonary fibrosis (IPF) patients without resting hypoxemia have not been elucidated. The purpose of this study was to assess the effect of ambulatory oxygen on dyspnea in IPFpatients without resting hypoxemia but with desaturation on exertion. METHODS: This was a double-blind, placebo-controlled, randomized crossover trial of ambulatory oxygen versus ambulatory air. Patients with IPF who had a partial pressure of arterial oxygen (PaO2) between 60 mm Hg and 80 mm Hg at rest, and desaturation of 88% or less in a room-air 6-min walk test were eligible. Patients underwent a standardized 6-min walk test and a 6-min free walk test under each ambulatory gas. Oxygen and air were provided at 4 L/min intranasally. Dyspnea was evaluated immediately, 1, and 2 min after the tests. RESULTS: Twenty patients (16 men), with a mean age of 73.5 (SD 4.1) years, % predicted forced vital capacity (FVC) of 71.0 (13.3) %, % predicted diffusion capacity for carbon monoxide (DLco) of 57.0 (13.3) %, and PaO2 of 72.5 (5.4) mm Hg were recruited. No significant differences in dyspnea were observed between ambulatory oxygen and air at each time point. However, some patients showed improvement in dyspnea with oxygen on an individual basis. CONCLUSIONS: Since oxygen provides no additional benefit over air in terms of exertional dyspnea for IPFpatients without resting hypoxemia, routine prescription of ambulatory oxygen is not recommended. However, assessment on an individual basis is necessary. Trial registration. UMIN Clinical Trial Registry; No.:UMIN000005098; URL:http://www.umin.ac.jp/ctr/.
Authors: Coenraad F N Koegelenberg; Gillian M Ainslie; Keertan Dheda; Brian W Allwood; Michelle L Wong; Umesh G Lalloo; Mohamed S Abdool-Gaffar; Hoosain Khalfey; Elvis M Irusen Journal: J Thorac Dis Date: 2016-12 Impact factor: 2.895
Authors: Dina Visca; Vicky Tsipouri; Letizia Mori; Ashi Firouzi; Sharon Fleming; Morag Farquhar; Elizabeth Leung; Toby M Maher; Paul Cullinan; Nick Hopkinson; Athol U Wells; Winston Banya; Jennifer A Whitty; Huzaifa Adamali; Lisa G Spencer; Piersante Sestini; Elisabetta A Renzoni Journal: Trials Date: 2017-04-28 Impact factor: 2.279
Authors: Susan S Jacobs; Jerry A Krishnan; David J Lederer; Marya Ghazipura; Tanzib Hossain; Ai-Yui M Tan; Brian Carlin; M Bradley Drummond; Magnus Ekström; Chris Garvey; Bridget A Graney; Beverly Jackson; Thomas Kallstrom; Shandra L Knight; Kathleen Lindell; Valentin Prieto-Centurion; Elisabetta A Renzoni; Christopher J Ryerson; Ann Schneidman; Jeffrey Swigris; Dona Upson; Anne E Holland Journal: Am J Respir Crit Care Med Date: 2020-11-15 Impact factor: 21.405
Authors: Anne Edvardsen; Inga Jarosch; Anita Grongstad; Laura Wiegand; Rainer Gloeckl; Klaus Kenn; Martijn A Spruit Journal: PLoS One Date: 2018-12-28 Impact factor: 3.240